A Single-Shot-Cure for Hepatitis C Being Tested at Duke
Share
Follow Us
Duke Clinical Research Unit to Conduct Hepatitis C Clinical Trial
Friday, March 22, 2013
RNAi-based therapeutics company Benitec Biopharma Limited announced Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), in Durham, North Carolina, as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential “one-shot-cure” for Hepatitis C (HCV).
SYDNEY and DURHAM, NC — “We are very excited to be working with Duke, a world renowned research institution with significant experience in this area,” said Peter French, Ph.D., Chief Executive Officer of Benitec. “The TT-034 trial marks the transition of Benitec to a clinical stage company. We expect that positive results from the trial will provide a value inflection point for the company, and also be a validation for our ddRNAi technology as an effective platform for therapeutics.”
Continue reading this entire article:
http://www.mdnews.com/news/2013_03/duke-clinical-research-unit-to-conduct-hepatitis-c-clinical-trial.aspx
